Lewandrowski Kai-Uwe, Bowirrat Abdalla, Pinhasov Albert, Sharafshah Alireza, Gold Mark S, Fuehrlein Brian, Elman Igor, Dennen Catherine, Thanos Panayotis K, Hanna Colin, Sipple Daniel, Baron David, Martire Gianni, Modestino Edward J, Jafari Nicole, Zeine Foojan, Sunder Keerthy, Lewandrowski Alexander Pl, Badgaiyan Rajendra D, Khalsa Jag, Pollack Aryeh, Fiorelli Rossano Kepler Alvim, Schmidt Sergio, Fliegelman Chynna, Lorio Morgan P, Makale Milan T, Blum Kenneth
Department of Orthopaedics, Fundación Universitaria Sanitas Bogotá D.C. Colombia.
Division of Personalized Pain Therapy Research, Center for Advanced Spine Care of Southern Arizona, Tucson, AZ.,USA.
Acta Sci Neurol. 2025 Apr 30;8(5):70-88.
In spite of the ongoing exquisite work of a multitude of researchers worldwide including governmental institutions like the National Institute on Drug Abuse (NIDA) and the National Institute on Alcohol Abuse and Alcoholism (NIAAA), and for example in the United States the FDA Medication Assisted Therapy (MAT) embracing Opioid Replacement Therapy (ORT) in 2022, 111,000 people prematurely died from opioid induced overdose. It is estimated that if treatment stays as usual by 2025 the death rate will increase to 165,00.Therefore, we are encouraging the scientific and clinical community to at least consider our "out of the box" thinking whereby we are proposing a new paradigm shift involving the " dopaminergic homeostatic modeling approach and Genetic screening to early identify preaddiction. In this novel approach following detoxification from for example powerful opioids, the patient is administered the validated RDSQ29 to access potential psychological profiling of Reward Deficiency Syndrome (RDS); obtain a cheek cell sample of the patient and perform genetic screening utilizing the Genetic Addiction Risk Severity (GARS); analyze mRNA to identify specific protein deficits/surfeits based on the measured reward genes involved in the Brain Reward Cascade (BRC); produce a customized pro-dopamine regulator (KB220) guided by GARS resulting polymorphisms; objectively employ the mRNA profiling assessment every week during the treatment phase to determine improvement; each treatment program could add on at their choice, for example, cognitive behavioral therapy, brain spotting, trauma therapy, electrotherapy (h-wave device to reduce pain, subluxation repair etc.) mindfulness, exercise, neuromodulation (PrTMS) amongst other modalities. The utilization of this model could prove beneficial to both substance and non-substance behavioral addictions (e. g. gaming). WC261 .
尽管全球众多研究人员,包括美国国立药物滥用研究所(NIDA)和美国国立酒精滥用与酒精中毒研究所(NIAAA)等政府机构,都在持续开展卓越的工作,例如美国食品药品监督管理局(FDA)的药物辅助治疗(MAT)在2022年纳入了阿片类药物替代疗法(ORT),但仍有11.1万人因阿片类药物过量导致过早死亡。据估计,如果治疗维持现状,到2025年死亡率将增至16.5万。因此,我们鼓励科学界和临床界至少考虑一下我们的“跳出框框”思维,即我们提出一种新的范式转变,涉及“多巴胺能稳态建模方法和基因筛查以早期识别成瘾前状态”。在这种新方法中,例如在从强效阿片类药物戒毒后,给患者服用经过验证的RDSQ29以获取奖励缺乏综合征(RDS)的潜在心理剖析;采集患者的颊细胞样本并利用遗传成瘾风险严重程度(GARS)进行基因筛查;分析信使核糖核酸(mRNA)以根据参与脑奖励级联(BRC)的测量奖励基因识别特定的蛋白质缺陷/过剩;根据GARS产生的多态性生成定制的促多巴胺调节剂(KB220);在治疗阶段每周客观地采用mRNA剖析评估来确定改善情况;每个治疗方案可以根据自身选择增加,例如认知行为疗法、脑点图疗法、创伤疗法、电疗法(用于减轻疼痛的h波装置、半脱位修复等)、正念、运动、神经调节(重复经颅磁刺激(PrTMS))等其他方式。这种模型的应用可能对物质成瘾和非物质行为成瘾(如游戏成瘾)都有益。WC261